Tratamiento integral de la dislipidemia diabética: beneficios y nuevas alternativas terapéuticas-Reference-Cited by-同舟云学术

Tratamiento integral de la dislipidemia diabética: beneficios y nuevas alternativas terapéuticas

Published:2010-04 Issue:9 Volume:134 Page:406-411
ISSN:0025-7753
Container-title:Medicina Clínica
language:es
Short-container-title:Medicina Clínica

Author:

Carmena Rafael,Ascaso Juan F.

Publisher

Elsevier BV

Subject

General Medicine

Reference47 articles.

1. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies;Huxley;Br Med J,2006

2. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23);Turner;Br Med J,1998

3. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD);Ryden;Eur Heart J,2007

4. Dyslipidaemia and hypertriglyceridaemia predict coronary heart disease events in middle-aged patients with NIDDM;Lehto;Diabetes,1997

5. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S);Pyo˘rälä;Diabetes Care,1997

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019;Clínica e Investigación en Arteriosclerosis;2019-05

2. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019;Clínica e Investigación en Arteriosclerosis (English Edition);2019-05

3. Iron Status Biomarkers and Cardiovascular Risk;Recent Trends in Cardiovascular Risks;2017-07-12

4. Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study;Clínica e Investigación en Arteriosclerosis;2014-05

5. Alteraciones del metabolismo de las lipoproteínas;Farreras-Rozman. Medicina Interna. Metabolismo y Nutrición. Endocrinología;2014